Hostname: page-component-cb9f654ff-hn9fh Total loading time: 0 Render date: 2025-08-29T13:09:27.187Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of the patient with long-term schizophrenia

Published online by Cambridge University Press:  02 January 2018

Ann Mortimer
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

At most, 15% of patients in Western countries remain free of relapse after their first episode of schizophrenia (Crow et al, 1986). Like many chronic illnesses, schizophrenia can be controlled by appropriate treatment, but there may be a gradual deterioration over time. This encompasses problems such as loss of self-care, communication and community skills; negative symptoms of poverty of affect and ideation; cognitive impairment; behaviour problems such as aggression; and poorly controlled positive symptoms.

Information

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 3 , Issue 6 , November 1997 , pp. 339 - 346
Copyright
Copyright © The Royal College of Psychiatrists 1997 

References

Anonymous (1994) Long-term management of people with psychotic disorders in the community. Drugs and Therapeutics Bulletin, 32, 73–77.CrossRefGoogle Scholar
Chadwick, P. & Birchwood, M. (1994) The omnipotence of voices. A cognitive approach to auditory hallucinations. British Journal of Psychiatry, 164, 190–201.CrossRefGoogle ScholarPubMed
Christison, G. W., Kirch, D. G. & Wyatt, R. J. (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin, 17, 217–245.CrossRefGoogle ScholarPubMed
Crow, T. J., MacMillan, J. F., Johnson, A. L. et al (1986) A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.CrossRefGoogle ScholarPubMed
Davis, J. M. (1975) Overview: maintenance therapy in psychiatry. 1: Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.Google Scholar
Davis, J. M., Metalon, L., Watanabe, M. D. et al (1994) Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741–773.CrossRefGoogle ScholarPubMed
Dye, S. M., Mortimer, A. M. & Lock, M. (1996) Clozapine versus treatment as usual in schizophrenia. Schizophrenia Research, 18, 126.CrossRefGoogle Scholar
Gerlach, J. & Peacock, L. (1995) New antipsychotics: the present status. International Clinical Psychopharmacology, 10, 39–48.Google ScholarPubMed
Green, M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321–330.Google ScholarPubMed
Guest, J. F., Hart, W. M., Cookson, R. F. et al (1996) Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics, 10, 59–67.Google Scholar
Kavanagh, D. J. (1992) Recent developments in expressed emotion and schizophrenia. British Journal of Psychiatry, 160, 601–620.CrossRefGoogle ScholarPubMed
Kemp, R., Hayward, P., Applewhaite, G. et al (1996) Compliance therapy in psychotic patients: a randomised controlled trial. British Medical Journal, 312, 345–349.CrossRefGoogle ScholarPubMed
Kerwin, R. (1995) Editorial: A revolution waiting to be prescribed. Hospital Update, June, 263–264.Google Scholar
Kerwin, R., Mortimer, A. M. & Lynch, K. (1997) Antipsychotic treatment of severely ill patients with schizophrenia. In Understanding Psychiatric Treatment of Mental Health Disorders (eds O'Mahony, G. & Lucey, J.) Chichester: John Wiley, in press.Google Scholar
Kingdon, D. (1994) Making care programming work. Advances in Psychiatric Treatment, 1, 41–46.CrossRefGoogle Scholar
Kissling, W. (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica, 89 (suppl. 32), 16–24.CrossRefGoogle Scholar
Liberman, R. P., Spaulding, W. D. & Corrigan, P. W. (1995) Cognitive-behavioural therapies in psychiatric rehabilitation. In Schizophrenia (ed. Weinberger, D. R.) pp. 605–625. Oxford: Blackwell Science.Google ScholarPubMed
McKenna, P. J. (1994) The natural history of schizophrenia. In Schizophrenia and Related Syndromes, pp. 52–72. Oxford: Oxford University Press.Google Scholar
Mortimer, A. M. (1994) Newer and older antipsychotics. A comparative review of appropriate use. CNS Drugs, 2, 381-3%.CrossRefGoogle Scholar
Mortimer, A. M. (1997) Cognitive deficit in schizophrenia – do neuroleptics make a difference? Pharmacology, Biochemistry and Behaviour, 56, 789–795.CrossRefGoogle Scholar
Siris, S. G. (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry, 163, 66–78.CrossRefGoogle Scholar
Turkington, D. (1996) Cognitive therapy in schizophrenia. Schizophrenia Monitor, 6, 1–3.Google Scholar
Turkington, D. & Kingdon, D. G. (1994) Cognitive Therapy of Schizophrenia. New York: Guilford Press.Google Scholar
Wing, J. K. & Brown, G. W. (1970) Institutionalism and Schizophrenia: A Comparative Study of Three Mental Hospitals, 1960–1968. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.